People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Spine BioPharma, Inc. | — | Pharmaceuticals | Series A | $51.8M | $63.9M | 2022 |
Frank R. Cammisa, MD at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Frank R. Cammisa, MD on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Marc R. Viscogliosi | 1 | 8 |
| John J. Viscogliosi | 1 | 7 |
| Thomas R. Bumol, PhD | 1 | 1 |
| Fran R. Magee | 1 | 1 |
| Jason J. Gallagher | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.